LXCHEM

- Trading window for dealing in securities of Laxmi Organic Industries Limited will remain closed from October 01, 2026. - Closure is pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. - Trading window will reopen 48 hours after the conclusion of the Board Meeting for approval of un-audited financial results for the quarter and half year ending September 30, 2026.

- Dr. Rajan Venkatesh resigned as Managing Director & Chief Executive Officer, effective November 13, 2026. - Mr. Harshvardhan Goenka, currently Executive Director, is appointed as the new MD & CEO for a period of five years, effective November 14, 2026. - This transition is part of the company's planned leadership succession process.

- Dr. Keshav Ruthia resigned as Chief Procurement Officer, effective October 31, 2026. - Mr. Salil Mukundan resigned as Chief Technology Officer, effective October 31, 2026. - Both are pursuing opportunities outside the company; Mr. Mukundan also cited health reasons. - The company stated it does not presently envisage like-for-like replacements for these roles.

- Allotment of 703,126 equity shares of ₹2/- each to eligible employees under ESOP-2020. The company's share capital increased from ₹55,44,23,134/- to ₹55,58,29,386/- post-allotment.

- The 37th Annual General Meeting (AGM) of Laxmi Organic Industries Ltd was held on August 5, 2026, via Video Conferencing/OAVM. - Key resolutions included adoption of financial statements for FY ended March 31, 2026, declaration of a final dividend, and re-appointment of directors. - All resolutions were duly passed.

- Reported strong Q1 FY27 performance with consolidated revenue up 40% YoY and EBITDA up 272% YoY, driven by volume growth (approx. 10%) and higher price realization. - Dahej project Phase 2 mechanical completion anticipated in Q2/Q3, with customer qualification in Q3 and ramp-up into FY28. FY27 total capex (including Dahej) estimated at INR125-150 crores. - Term debt has peaked at ~INR6,100 million, with net debt equity around 0.3x. Debt repayment expected to start next year for 5 years. - Incremental quarterly depreciation of INR7-7.5 crores expected from Q2 FY27 due to Dahej Phase 2 capitalization. - Essentials business EBITDA expected to be in mid-single-digit range over the cycle, while Specialty margins are targeted at 20-25% over a 2-3 year period. - Project Vaayu (electrochemical fluorination) mechanical completion in early Q3, with revenue contributions expected from FY28.

- Recording of the Analyst / Institutional Investors' meeting for the quarter ended June 30, 2026, is now available for download via the provided link. - The meet was held on July 30, 2026, to discuss the company's performance.

- Consolidated Revenue ₹968.34Cr vs ₹692.93Cr (▲39.74% YoY) - EBITDA ₹114.33Cr vs ₹30.75Cr (▲271.76% YoY) - PAT ₹67.72Cr vs ₹21.39Cr (▲216.56% YoY) - EBITDA Margin 11.81% vs 4.44% (▲737bps)